| Literature DB >> 24478770 |
Ariko Miyake1, Yasuyuki Miyazaki1, Mikako Fujita2, Masako Nomaguchi1, Akio Adachi1.
Abstract
Entities:
Keywords: HIV-2; PPM; SIV; Vpr; Vpx
Year: 2014 PMID: 24478770 PMCID: PMC3904113 DOI: 10.3389/fmicb.2014.00024
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Figure 1Steady-state levels of various Vpx-PPM mutants in cells as monitored by Western blotting. (A) Structure of the FLAG-tagged HIV-2 GL-AN Vpx construct. Numerals above the schema represent amino acid numbers of the Vpx protein. Positions of lysine and glutamine residues mutated are indicated. (B) Expression of Vpx-PPM mutants in the presence of a proteasome inhibitor MG-132 or a lysosome inhibitor Bafilomycin A1. (C) Expression of lysine-mutants with or without 106/4A mutation. (D) Expression of Q76A mutants with or without 106/4A mutation. For (B) to (D) experiments, 293T cells were transfected with the plasmids indicated, and harvested for Western blotting 24 h later. To examine lysosomal and proteasomal degradation processes (B), 100 nM of BafilomycinA1 (Yoshimori et al., 1991) and 7.5 μM of MG-132 (McCulley and Ratner, 2012) were added at 5 and 16 h post-transfection, respectively. WT, pEF-Fvpx; ΔVpx, pEF-FxSt.